Abstract:Summary Background Targeted next-generation sequencing (NGS) can rapidly and simultaneously detect mutations associated with resistance to tuberculosis drugs across multiple gene targets. The use of targeted NGS to diagnose drug-resistant tuberculosis, as described in publicly available data, has not been comprehensively reviewed. We aimed to identify targeted NGS assays that diagnose drug-resistant tuberculosis, determine how widely this technology has been used, and assess the diagnostic accuracy of these assays. Methods In this systematic review and meta-analysis, we searched MEDLINE, Embase, Cochrane Library, Web of Science Core Collection, Global Index Medicus, Google Scholar, ClinicalTrials.gov , and the WHO International Clinical Trials Registry Platform for published and unpublished reports on targeted NGS for drug-resistant tuberculosis from Jan 1, 2005, to Oct 14, 2022, with updates to our search in Embase and Google Scholar until Feb 13, 2024. Studies eligible for the systematic review described targeted NGS approaches to predict drug resistance in Mycobacterium tuberculosis infections using primary samples, reference strain collections, or cultured isolates from individuals with presumed or confirmed tuberculosis. Our search had no limitations on study type or language, although only reports in English, German, and French were screened for eligibility. For the meta-analysis, we included test accuracy studies that used any reference standard, and we assessed risk of bias using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. The primary outcomes for the meta-analysis were sensitivity and specificity of targeted NGS to diagnose drug-resistant tuberculosis compared to phenotypic and genotypic drug susceptibility testing. We used a Bayesian bivariate model to generate summary receiver operating characteristic plots and diagnostic accuracy measures, overall and stratified by drug and sample type. This study is registered with PROSPERO, CRD42022368707. Findings We identified and screened 2920 reports, of which 124 were eligible for our systematic review, including 37 review articles and 87 reports of studies collecting samples for targeted NGS. Sequencing was mainly done in the USA (14 [16%] of 87), western Europe (ten [11%]), India (ten [11%]), and China (nine [10%]). We included 24 test accuracy studies in the meta-analysis, in which 23 different tuberculosis drugs or drug groups were assessed, covering first-line drugs, injectable drugs, and fluoroquinolones and predominantly comparing targeted NGS with phenotypic drug susceptibility testing. The combined sensitivity of targeted NGS across all drugs was 94·1% (95% credible interval [CrI] 90·9–96·3) and specificity was 98·1% (97·0–98·9). Sensitivity for individual drugs ranged from 76·5% (52·5–92·3) for capreomycin to 99·1% (98·3–99·7) for rifampicin; specificity ranged from 93·1% (88·0–96·3) for ethambutol to 99·4% (98·3–99·8) for amikacin. Diagnostic accuracy was similar for primary clinical samples and culture isolates overall and for rifampicin, isoniazid, ethambutol, streptomycin, and fluoroquinolones, and similar after excluding studies at high risk of bias (overall sensitivity 95·2% [95% CrI 91·7–97·1] and specificity 98·6% [97·4–99·3]). Interpretation Targeted NGS is highly sensitive and specific for detecting drug resistance across panels of tuberculosis drugs and can be performed directly on clinical samples. There is a paucity of data on performance for some currently recommended drugs. The barriers preventing the use of targeted NGS to diagnose drug-resistant tuberculosis in high-burden countries need to be addressed. Funding National Institutes of Allergy and Infectious Diseases and Swiss National Science Foundation.

A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing

A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing

121. Improving Predictive Value of Phase 2a TB Drug Development Models Through PET/CT Imaging (nexgen EBA)

Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 Drugs

Rapid detection of multidrug resistance in tuberculosis using nanopore-based targeted next-generation sequencing: a multicenter, double-blind study

Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis

High-throughput nanopore targeted sequencing for efficient drug resistance assay of Mycobacterium tuberculosis

Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples

Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.

Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis

Diagnostic Accuracy of Nanopore Sequencing for Detecting Mycobacterium tuberculosis and Drug-Resistant Strains: A Systematic Review and Meta-Analysis

Mycobacterium Tuberculosis Functional Genetic Diversity, Altered Drug Sensitivity, and Precision Medicine.

Nanopore-based targeted sequencing test for direct tuberculosis identification, genotyping, and detection of drug resistance mutations: a side-by-side comparison of targeted next-generation sequencing technologies

Comparative Utility of Genetic Determinants of Drug Resistance and Phenotypic Drug Susceptibility Profiling in Predicting Clinical Outcomes in Patients with Multidrug-Resistant Mycobacterium Tuberculosis

Nanopore-based targeted next-generation sequencing of tissue samples for tuberculosis diagnosis

Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis

Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships

Plasma Concentrations of Second-Line Antituberculosis Drugs in Relation to Minimum Inhibitory Concentrations in Multidrug-Resistant Tuberculosis Patients in China: a Study Protocol of a Prospective Observational Cohort Study.

Targeted next-generation sequencing of Mycobacterium tuberculosis from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh

Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach

Diagnostic Accuracy of Nanopore Sequencing for the Rapid Diagnosis of Pulmonary Tuberculosis: A Protocol for a Systematic Review and Meta-Analysis